Becker et al. discovered that the simultaneous inhibition of CSF1R and IL-6R could prevent cDC2 from transitioning into immunosuppressive tumor-induced DC3, thereby improving the therapeutic potential of DC-driven treatments [103]. The gene discussed is CSF1R; the disease is neoplasm.